



Fresenius Kabi
Canada Ltd.

165 Galaxy Blvd, Suite 100
Toronto, Ontario
Canada M9W 0C8
T: 905.770.3711
F: 844.513.1522
W: fresenius-kabi.ca

April 1, 2022

Midazolam, Milrinone, Tobramycin Supply Notification

Dear Valued Customer,

Fresenius Kabi Canada regrets to advise that due to production delays, we will be placing and modifying allocations for the following products, effective today, **April 1, 2022**:

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Supply Status
02242905	C410202	922572	23015	Midazolam Injection 5 mg/mL MD Vial 2 mL	100% Allocation
02244622	C601710	922596	3087	Milrinone Lactate Injection 1 mg/mL SD Vial 10 mL	Increased allocation to cover 100% of 10 mL demand, plus 50% of 20 mL demand on a mL:mL basis
02244622	C601720	922602	2915	Milrinone Lactate Injection 1 mg/mL SD Vial 20 mL	Reduced to 50% allocation. Remaining 50% demand to be covered by 10mL on a mL:mL basis
00533688	C300351	928781	297481	Tobramycin for Injection 1.2 g PBP Vial 50 mL	100% Allocation

We recognize the difficulties and inconvenience that you may encounter as a result of these allocations, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact Customer Service at (877) 821-7724.

Sincerely,

George Shamsoun
Associate Director – Marketing, IV Drugs
george.shamsoun@fresenius-kabi.com